Chemotherapy pain may be eased by jet-lag drug
Painful side effects from cancer medicines could be tackled with a drug that eases the effects of jetlag...
List view / Grid view
Painful side effects from cancer medicines could be tackled with a drug that eases the effects of jetlag...
Artemisinin, a potent anti-malarial drug, has been widely hailed as a promising alternative cancer treatment...
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
Taxanes inhibit cell division and make cancer cells sensitive to radiation therapy, a current study has investigated the underlying mechanisms of this action...
Research published in The Journal of Experimental Medicine suggests potential treatment for glioblastoma
Brazilian researchers have investigated whether cisplatin and 5-FU would interfere with the protein pRB...
Researchers in Japan have designed a small 'body-on-a-chip' device that can test the side effects of drugs on human cells...
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK...
Researchers have developed a method that could make magnetic resonance imaging (MRI) multicoloured - a strategy that could serve as a research tool and even aid disease diagnosis...
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF...
Researchers have identified a drug regimen administered prior to and after surgery that significantly reduces the risk of post-surgical cancer recurrence...
Researchers have discovered properties of the precious metal that allow catalytic abilities to be accessed in living things without any side effects...
Engineers have devised a non-invasive way to assess a cell's mechanical properties simply by observation...
After the first half of 2017 biopharma investors are in a position to be exuberant, the threat of US price controls that have overshadowed the sector for a year have largely disappeared...
Russian biotech company BIOCAD plans to leverage competitive advantages to take 5% of the European medicines market